gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · SINTHealthcareSurgical Instruments

SiNtx Technologies, Inc. Common Stock (SINT)

$1.66−3.49%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$1.66▼ 48.29% in range
Nov 4, 2025Low $1.40 · High $4.26Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

SiNtx Technologies closed at $1.66 on Nov 4, down 3.49%, 61.0% below its 52-week closing high. Volume of 56.0K shares was 1.70× its 20-day average (above normal).

Split-adjusted performance: -23.9% over one month, -30.8% over six months, -50.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $452K, up 199.3% from a year earlier, with a net margin of -803.5%.

Short interest was 136.4K shares at the Oct 15 settlement, up 36.8% from the prior report (4.3% of float, 1.1 days to cover).

Market cap$12.5M7.6M shares
Revenue · quarter$452.0K+199.3% YoY
Diluted EPS$-0.75—
P/E · TTM—P/S 9.4×
Net margin-803.5%Gross 61.5%
Dividend yieldNone
52-week range1.40 – 4.26−61.0% from high
Volume56.0K1.70× 20-day avg
Volatility · 60d65.6%Annualised
Short % of float4.3%1.1 days to cover
Net cash$3.5MCash $3.6M
Next earnings—Not scheduled
Split-adjusted performance
1W −4.6%1M −23.9%3M +1.8%6M −30.8%YTD −57.0%1Y −50.3%3Y −98.1%5Y −100.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum30
Revenue growth99
Net margin8
Value (low P/E)—
Size17

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short136.4K+36.8% vs prior
Days to cover1.1Settled Oct 15
% of float4.3%
Short vol. 10d49.5%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
SINTSiNtx Technologies$1.66−3.49%−30.8%+199.3%−803.5%—$12.5M
GUTSFractyl Health$0.9725+8.27%−89.0%———$12.9MCompare
FEMYFemasys$1.44+2.86%−84.1%−18.9%−1346.8%—$12.1MCompare
PAVMPAVmed$1.66−8.79%−76.3%+450.0%−16603.0%—$13.3MCompare
CTSOCytosorbents$4.56+0.44%−60.0%+0.2%−45.9%—$14.4MCompare
ICUSeaStar Medical Holding$2.04+2.00%−58.1%+82.0%−606.5%—$10.8MCompare
MODDModular Medical$1.67−5.65%−57.3%———$15.9MCompare
PMIPicard Medical$7.19−7.58%−38.0%—−191.6%—$16.8MCompare
RVPRetractable Technologies$0.5660+0.71%−18.3%−31.1%38.5%—$16.9MCompare

News about SiNtx Technologies

All news →
What Makes SINTX TECHNOLOGIES (SINT) a New Buy StockZacks Investment Research · Oct 8, 2026▲ PositiveSINTX Technologies Engages Veteran MedTech Executive Chris Lyons and Southern Metrics to Establish Strategic Opportunity Management ProgramGlobeNewswire Inc. · Jul 23, 2026▲ Positive

Quick answers

What does SiNtx Technologies do?
SINTX Technologies Inc is a biomaterials company that develops, manufactures, and commercializes patented and proprietary silicon nitride ceramic biomaterials, composites, devices, and related ceramics technologies for other medical and specialized industrial applications. SINTX has 20 years' experience innovating silicon nitride technologies and operates under a quality management system certified to ISO 13485:2016 and AS9100D, with a product portfolio that includes insulators for Tier 1 aerospace suppliers, the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System for reconstructive surgery, OEM manufacturing of FDA-cleared spinal implants, and its SiNERGY technology platform being developed for biocomposite and 3D printing applications.
What is SINT's market cap?
$12.55M, based on the Nov 4 close of $1.66.
Does SiNtx Technologies pay a dividend?
No regular cash dividend has been paid in the last year.
How much of SINT is sold short?
136.4K shares, 4.3% of float, as of Oct 15, 2026.
What sector is SINT in?
Healthcare, in the Surgical Instruments industry.

About SiNtx Technologies

SINTX Technologies Inc is a biomaterials company that develops, manufactures, and commercializes patented and proprietary silicon nitride ceramic biomaterials, composites, devices, and related ceramics technologies for other medical and specialized industrial applications. SINTX has 20 years' experience innovating silicon nitride technologies and operates under a quality management system certified to ISO 13485:2016 and AS9100D, with a product portfolio that includes insulators for Tier 1 aerospace suppliers, the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System for reconstructive surgery, OEM manufacturing of FDA-cleared spinal implants, and its SiNERGY technology platform being developed for biocomposite and 3D printing applications.

HQ: Salt Lake City, UT32 employeesListed Feb 13, 2014sintx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology